Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewBCN HEALTH publica un estudio evaluando la incidencia y el coste de la enfermedad renal cr...
BCN HEALTH has published in the Journal of Medical Economics a study analyzing the incidence, management, and associated costs of chronic kidney disease (CKD) in Spain between 2011 and 2017. Based on
-
NewNatac records revenues of €31.88 million through mid-October
The company expects to close the year with sales exceeding €50 million and an EBITDA above €20 million
-
NewGENESIS Biomed participated in the strategic development of AptaTargets, which has license...
AptaTargets signed in May 2025 a licensing agreement with Merck for the clinical development and global commercialisation of ApTOLL, an aptamer with neuroprotective effect for the treatment of
-
NewORYZON to participate in upcoming events in November
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:
-
-
EventRare Disease Summit
-
-
-
-
EventBIO360
-
-
EventBIOSEED
-
EventBIOTECH SHOWCASE
-
-
NewGlycobasque 8 brought together leading international figures in glycosciences in San Sebas...
The eighth edition of Glycobasque turned San Sebastián into a hub for glycoscience research on October 23–24. The meeting, led by Asparia Glycomics in collaboration with the research centers CIC
-
-
Press releaseInnovation, research, and the future: biotechnology sets the course for psoriasis treatmen...
Biotechnology enables the development of more effective and personalized treatments for chronic inflammatory diseases such as psoriasis, improving the quality of life for millions of people. Inhibitec
-
NewWhen biotechnology puts itself in the patient’s skin
The biotech company Inhibitec is advancing the development of an antibody targeting the BAMBI molecule, with therapeutic potential for both psoriasis and psoriatic arthritis.
-
NewPublic research at the Barcelona Science Park – UB reaches a record investment of €84 mill...
The public research ecosystem of the Barcelona Science Park (PCB-UB) continues to expand, achieving 84.6 million euros in funding in 2024, 20.8% more than the previous year and the highest figure ever
-
NewBiotechnology emerges as Spain’s key tool against climate change: nearly 600 solutions dev...
At AseBio, our Sustainability Commission has prepared the report “Biotechnology Applied to the Green Transition,” which analyzes the solutions, areas of action, distribution, and challenges of our
-
Press release
Biotechnology emerges as Spain’s key tool against climate change: nearly 600 solutions dev...
In the face of climate change, ecosystem degradation, and population growth, moving toward a sustainable economic model is urgent. The green transition stands as the essential roadmap, with
